Market Update: Moderna Inc (MRNA) Sees Negative Movement, Closing at 26.00

Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.

In the latest session, Moderna Inc (NASDAQ: MRNA) closed at $26.00 down -2.51% from its previous closing price of $26.67. In other words, the price has decreased by -$2.51 from its previous closing price. On the day, 10.64 million shares were traded.

Ratios:

For a deeper understanding of Moderna Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.14 and its Current Ratio is at 4.22. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.07.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on March 13, 2025, initiated with a Neutral rating and assigned the stock a target price of $40.

On February 18, 2025, Barclays Downgraded its rating to Equal Weight which previously was Overweight and also lowered its target price recommendation from $111 to $45.

Goldman Downgraded its Buy to Neutral on January 29, 2025, whereas the target price for the stock was revised from $99 to $51.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 11 ’25 when Hussain Abbas sold 312 shares for $28.00 per share. The transaction valued at 8,736 led to the insider holds 580 shares of the business.

Hussain Abbas bought 312 shares of MRNA for $8,736 on Jun 11 ’25. On Mar 03 ’25, another insider, Bancel Stephane, who serves as the Chief Executive Officer of the company, bought 160,314 shares for $31.22 each. As a result, the insider paid 5,004,318 and bolstered with 9,210,686 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 3.17 while its Price-to-Book (P/B) ratio in mrq is 1.00.

Stock Price History:

Over the past 52 weeks, MRNA has reached a high of $145.74, while it has fallen to a 52-week low of $23.15. The 50-Day Moving Average of the stock is -1.04%, while the 200-Day Moving Average is calculated to be -36.69%.

Shares Statistics:

A total of 387.00M shares are outstanding, with a floating share count of 342.49M. Insiders hold about 11.44% of the company’s shares, while institutions hold 72.20% stake in the company.

Leave a Reply

Your email address will not be published. Required fields are marked *

DWinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.